Book Review Strategies of Adjuvant Therapy

por Middleton, M
Publicado 2001

Adjuvant interferon in the treatment of melanoma

por Middleton, M R
Publicado 1999

Adjuvant interferon in the treatment of melanoma – reply

por Middleton, M R
Publicado 2000

Adjuvant interferon in melanoma – a resurrection?

por Middleton, M R, Thatcher, N
Publicado 2001

Progress towards Operation of a Deuterium Cold Neutron Source at the NCNR

por Jurns, J, Middleton, M, Williams, R
Publicado 2020

Healthcare for Asylum Seekers and Refugees; A Scoping Review

por Middleton, M, Coyle, R, O'Donovan, D
Publicado 2023

A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage

por Findlay, J. M., Middleton, M. R., Tomlinson, I.
Publicado 2015

A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.

por Jayson, G. C., Middleton, M., Lee, S. M., Ashcroft, L., Thatcher, N.
Publicado 1998

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma

por Middleton, M R, Lorigan, P, Owen, J, Ashcroft, L, Lee, S M, Harper, P, Thatcher, N
Publicado 2000

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours

por Dean, E, Middleton, M R, Pwint, T, Swaisland, H, Carmichael, J, Goodege-Kunwar, P, Ranson, M
Publicado 2012

Melanoma in Buckinghamshire: Data from the Inception of the Skin Cancer Multidisciplinary Team

por Cubitt, J. J., Khan, A. A., Royston, E., Rughani, M., Middleton, M. R., Budny, P. G
Publicado 2013

A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update

por Biswas, S, Wrigley, J, East, C, Hern, A, Marshall, A, Dunn, J, Lorigan, P, Middleton, M, Corrie, P
Publicado 2008

Societal preference values for advanced melanoma health states in the United Kingdom and Australia

por Beusterien, K M, Szabo, S M, Kotapati, S, Mukherjee, J, Hoos, A, Hersey, P, Middleton, M R, Levy, A R
Publicado 2009

Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma

por Donskov, F, Middleton, M, Fode, K, Meldgaard, P, Mansoor, W, Lawrance, J, Thatcher, N, Nellemann, H, von der Maase, H
Publicado 2005

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

por Cummings, J, Zweifel, M, Smith, N, Ross, P, Peters, J, Rustin, G, Price, P, Middleton, M R, Ward, T, Dive, C
Publicado 2012

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer

por Khan, O A, Ranson, M, Michael, M, Olver, I, Levitt, N C, Mortimer, P, Watson, A J, Margison, G P, Midgley, R, Middleton, M R
Publicado 2008

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer

por Khan, O A, Ranson, M, Michael, M, Olver, I, Levitt, N C, Mortimer, P, Watson, A J, Margison, G P, Midgley, R, Middleton, M R
Publicado 2009

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer

por Khan, O A, Blann, A D, Payne, M J, Middleton, M R, Protheroe, A S, Talbot, D C, Taylor, M, Han, C, Patil, M, Harris, A L
Publicado 2011

Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate

por Khan, O A, Blann, A D, Payne, M J, Middleton, M R, Protheroe, A S, Talbot, D C, Taylor, M, Han, C, Patil, M, Harris, A L
Publicado 2012

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma

por Lee, R J, Gremel, G, Marshall, A, Myers, K A, Fisher, N, Dunn, J A, Dhomen, N, Corrie, P G, Middleton, M R, Lorigan, P, Marais, R
Publicado 2018